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A range of proteins has been recognized as mediators/hypothetical receptors for hepatitis B virus
(HBV), but the results are conflicting and inconclusive especially regarding their biological significance.
This study was aimed at identifying a novel HBV-interacting protein which would provide a better
understanding of its transport in blood, attachment, fusion and entry into hepatocytes. Serum samples
positive for HBV confirmed by PCR were subjected to ammonium sulfate fractionations at 50, 75, 100%,
saturation. PCR of each fraction demonstrated amplification of HBV in 100% fraction. Protein analysis
by SDS PAGE of fractions showed one band of approximately 69 kDa protein, in 100% fraction. The
100% fraction band was excised from gel and sequence was determined by MALDI TOF which showed
mass values from 705 to 3722. Mass spectrometry of trypsinized 69 kDa species revealed peptide
sequences that covered 54% of the serum albumin precursor amino acid sequence, with pI of 5.9.
Western blot, carried out using primary anti-albumin precursor antibody, further validated this protein.
This study establishes that Hepatitis B Virus binds to albumin precursor, suggesting its role in the
initiation of HBV infection and hence may offer new therapeutic strategies against HBV infection.
Key words: Albumin precursor, hepatitis B virus, mass spectrometry, western blotting.
INTRODUCTION
The Hepatitis B Virus (HBV) was discovered nearly 40
years back, yet the search for a receptor or a carrier
protein is still going on. Despite considerable advances in
the understanding of the nature of HBV disease, many of
the steps in the virus life cycle remain unclear. Virus
transport in blood, attachment to permissive cells, fusion
and penetration through cell membranes and subsequent
genome release, are largely an ambiguity. Current knowledge on the early steps of HBV life cycle has mostly
evolved from molecular cloning and studies of the
infection of duck hepatitis B virus (DHBV). However,
considering the difference of composition and sequence
between the surface protein of HBV and entry may be
restricted (Lu and Block, 2004). Efforts to identify the cell

surface receptor(s) for HBV have been hampered by the
limitations of the in vitro models of HBV infection and non
availability of in vivo models. A recent study (Deng et al.,
2007), has suggested interaction (virus binding, virus
capture, and cell attachment) of lipoprotein lipase (LPL),
with PreS and HBV particles, but this too has been an in
vitro study. Similarly, an array of proteins has been described
as putative receptors for HBV; however, the biological
significance of these molecules has not been confirmed
(Barrera et al., 2005). This study was aimed at identifying
a novel HBV-interacting protein which would provide a
better understanding of its transport in blood, its attachment to hepatocytes, fusion and entry into the cells.
MATERIALS AND METHODS

*Corresponding author. E-mail: baigsaeeda@yahoo.com,
saeedabaig@zmu.edu.pk. Tel: (0092-9221) 5862937. Fax:
(0092-9221) 5862940.

All work was done at molecular biology laboratory at Aga Khan
University, Karachi, Pakistan. Serum samples collected (by
informed consent) from patients attending clinic at Ziauddin Medical
University were stored at minus 70ºC until analysed. Only HBV
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positive sera detected by HBsAg (ELISA-MUREX kit by Abbot
Laboratory) were included in this study. Ethical approval for this
study was granted by the Ziauddin University ethical review committee.
Protein precipitation and quantification
Proteins from HBV positive serum were fractionated by using varying concentrations of NH4(SO4)2 as described by Spadaro et al.
(2003). Serum samples (200 µl each) of HBV infected high titer
patients were subjected to ammonium sulphate precipitation and
four fractions at 50, 75, 100 and supernatant of 100% were collected. The protein yield in each fraction was quantified by Bradford
Method. A standard curve was drawn for this purpose, using
solutions of bovine serum albumin (BSA) as standard, according to
the method of Gornall et al. (1949).
DNA extraction and PCR amplification
In order to detect HBV associated protein fraction, DNA extraction
was performed on all four fractions namely, 50, 75, 100% and the
supernatant, using a DNA extraction kit (QIA AMP DNA mini kit 250
reactions Cat #51306).
PCR was performed to ascertain which fraction holds the activity
of HBV, by using primers for HBV, P7F and P7R (from Gene Link
NY, USA), for core protein. For reference HBV Clone of 620bp
(reference strain; AF460235) was used as an appropriate positive
control and to monitor the efficacy of PCR protocol. Reaction mix
for each tube contained DNA (10 µl), 10x buffer (50 mM KCl, 10
mM Tris pH 8.3), MgCl2 (2 mM), dNTPs (200 M), P7F and P7R (20
pmol each), H2O (28.7 µl), Taq polymerase (2.5 U), with the Cycling
as 94°C pre denaturation for 2 min, 94°C for 30 s, 55°C for 30 s,
72°C for 1 min for 35 cycles, 72°C for 7 min, and 4°C hold. To the
positive control tube instead of DNA 1.0 µl of Clone template plus
9.0 µl of H2O was added. For visualization of PCR product 2.5%
agarose was prepared in 1x TBE buffer. The gel was run in 1x TBE
buffer at a voltage of 90V. The amplified bands were visualized on
Gel Doc system Quantity One (BioRad company, USA) with a
medium or long wavelength (e.g. 300 nm) UV light and recorded in
a TIFF file.

gels and in-gel digested with trypsin using a Mass PREP robotic
protein-handling system (Micromass). The samples were loaded
onto the ZipTip by pipetting 20 times and washed using 10 l 0.1%
TFA twice. The tryptic fragments were eluted with 60% acetonitrile /
1% acetic acid. The tryptic fragments were mass analyzed by
matrix-assisted laser desorption ionization (MALDI) mass spectrometry (Voyager DE-PRO; Applied Biosystems) and Q-TOF Ultima
API (Micromass) was employed for sequence information. For LCMS the material obtained after in-gel digestion was directly applied
on a Q-TOF Ultima API (Micromass) instrument coupled with online CapLC (Waters). A column from Genetec, PepMap C18 3 m,
100°A, 75 m x 150 mm was employed for separation of peptides
prior to entry into mass spectrometer. For peptides separation,
samples were applied on the column in buffer A containing 5%
acetonitrile in water and 0.1% formic acid, eluted with buffer B,
containing 95% acetonitrile in water and 0.1% formic acid. The
(M+H)+ values for the peptide fragments produced by trypsin
digestion were used for protein identification with MS-FIT program
on Protein Prospector. Proteins were identified from peptide mass
data
by
using
BLAST
search
at
http://www.ncbi.nlm.nih.gov/blast/blast.cgi
Western blotting
The protein fractions were solubilized in Laemmli sample buffer
(Laemmli, 1970) and resolved on 10% SDS PAGE. Subsequently,
the protein fractions were blotted on to a nitrocellulose (HybondTM
ECL, GE Healthcare Life Science)
Nitrocellulose membrane was pre-wet with distilled water and
then soaked in transfer buffer. The cassette was opened into a tray
filled with transfer buffer. A foam sponge was placed on the open
submersed cassette and pressed gently to expel any air bubble.
Four sheets of blotting paper were placed on the sponge and the
membrane was placed on the blotting paper. The gel was then
placed on the membrane. All air bubbles were removed by gently
rolling a glass pipette over the gel. The gel was then covered with
four sheets of blotting paper and a sponge (6 mm). The cassette
was then closed and inserted into the transfer unit containing
transfer buffer. A cooling system was connected to the heat
exchanger outlet of the tank and water was circulated at 10°C. A
magnetic stirrer was placed in the buffer tank. Transfer was allowed
at 250 mA for 4 h.

Polyacrylamide Gel Electrophoresis (PAGE)
Proteins fractionated by ammonium sulphate were analyzed by
SDS-PAGE to determine the molecular size protein species present
in each fraction (Spadaro et al., 2003). Each precipitated fraction
was washed with ammonium sulfate solution at the respective salt
concentration to improve the yield. Protein samples of fractions 50,
75 ,100% and supernatant respectively were dissolved in sample
diluting buffer in the ratio of 1:1 by boiling in a water bath for 3 min
and resolved on 10% SDS PAGE . Electrophoresis was performed
using tris-glyine buffer at constant voltage of 90V/plate of 10 mm
length and 1 mm in thickness, for approximately 1 h; or till the dye
migrated 95% of the gel length. The gels were stained with
Coomassie Brilliant Blue-R (CBBR) and de-stained with glacial
acetic acid (10%) to visualize the protein components.
The 69 kDa band (separated out on 100% fraction) was extracted
from the SDS-PAGE gel and digested with trypsin, and the peptide
masses were examined by mass spectrophotometry.
MALDI TOF
Mass spectrophotometry of the excised band from gel of 10% SDS
PAGE was done as described by Hong et al. (2004). Protein bands
were excised manually from Coomassie Blue stained SDS PAGE

Incubation of the nitrocellulose membrane with antibody
The albumin precursor protein was detected with primary monoclonal antibody (Sigma-Aldrich, Saint Louis Missouri, USA), that is,
anti-albumin precursor antibody (1:500) in conjugation with the
horse radish peroxidase conjugated secondary antibody (1:10,000)
and visualized using ECL detection kit (GE Healthcare) according
to the manufacturers’ instructions.

RESULTS
Amplification of HBV in 100% fraction
A band of 140 bp length (nucleotide 2298 to 2436) of the
C gene of HBV DNA was found more prominent in the
PCR of 100% fraction signifying HBV activity along with
the protein precipitated on 100% saturation (Figure 1).
The first two fractions (50 and 75%) did not show any
noticeable amplification. The positive control HBV clone
used as the template amplified a 140 bp fragment insert
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revealed no band (Figure 2). Thus PCR negative fractions establish that globulins and albumins do not carry
HBV and it is the third fraction that grasped all the
attention.
Mass Spectrophotometry
albumin precursor
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3

4

5

6

Figure 1. PCR amplification to determine the HBV activity.
Lane 1, DNA 100 bp ladder, lane 2, supernant of 100%
ammonium sulfate fraction, lane 3, amplified product of 140bp
was observed in 100% ammonium sulfate precipitated
fraction, lane 4, ammonium sulfate 75% fraction, lane 5,
ammonium sulfate 50% fraction and lane 6, HBV Clone was
used as positive control.

identifies

69

kDa

as

The peptide sequences of 69 kDa band, excised from the
lane of 100% fraction on SDS-PAGE gel and digested
with trypsin, were examined by mass spectrometry. The
results, based on MALDI-TOF MS showed mass values
from 705 to 3722 (Figure 3). Analysis of these masses
through Protein Prospector revealed peptide sequences
that covered 54% of the Serum Albumin Precursor amino
acid sequence, with molecular weight of 69 kDa, pI of
5.9/.
Western blotting confirms albumin precursor

kDa

Analysis shows a high expression of albumin precursor
protein at position which coincides with the 69 kDa band
rd
of 3 fraction (100%) on SDS PAGE, showing a proteinprimary antibody-secondary antibody-enzyme complex,
proving the presence of albumin precursor (Figure 4).
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Figure 2. Proteins fractionated by ammonium
sulphate were analyzed by SDS-PAGE. Lane 1,
shows SDS-PAGE low molecular weight standard,
lane 2, ammonium sulfate 50% fraction, lane 3,
ammonium sulfate 75% fraction and lane 4,
ammonium sulfate 100% fraction.

The normal controls (HBsAg negative patients) did not
give any results on PCR amplification (results not
shown).
A single band of 69 kDa in 100% fraction on SDS
The first two fractions, namely 50 and 75% salt concentrations, revealed presence of two major groups of proteins; globulins and albumins respectively, as analyzed
by SDS page. The third fraction (100%) presented a
single band at 69 kDa position and the fourth fraction re-

This study identifies albumin precursor as HBV binding
protein which may be involved in interaction with the
membrane receptor mediating the attachment to the liver
cells. The data presented demonstrate the presence of
HBV only in the fraction which was later identified to contain albumin precursor. It appears that albumin precursor
of 69 kDa protein is similar to albumin yet has different
characteristics in terms of molecular weight and no cross
reactivity with antibody to albumin.
Since the discovery of HBV despite intensive efforts, a
clear understanding about receptor or binding protein for
HBV remains elusive. It is known that HBV, for its entry
into the hepatocyte requires a binding protein and a cellular receptor (Lonberg and Philipson, 1981). Once it
passes the attachment and entry steps of infection, HBV
is able to replicate freely in hepatic cells. Many proteins
have been identified as HBV envelope binding proteins
with a proposed role as mediators in HBV attachment to
the hepatocyte. At the same time, many theories have
been proposed regarding HBV attachment and entry into
hepatocytes but none of these theories or binding proteins have been thoroughly proved or investigated.
In this study, the albumin precursor precipitated along
with the third fraction (100% ammonium sulfate saturation) of serum as was proved by analysis of this fraction
by mass spectrometry and western blotting. It is important to note that this was the only fraction that turn out to
be PCR positive for HBV, while all other fractions
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Figure 3. MALDI-TOF MS of 69 kDa protein obtained from one piece of silver-stained SDS- PAGE gel.
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Figure 4. Western blot analysis of albumin precursor
protein after ammonium sulfate fractionations of serum
samples. Samples were HBV positive serum was
fractionated; lane 1, with 50%, lane 2, 75% and lane 3,
100% ammonium sulfate.

mained negative. This also suggests that a strong affinity
exists between HBV and the precipitated protein in this
fraction. The protein band of 100% fraction on SDS
PAGE was not as intense as the band on western blotting. One reason for this difference could be the binding
affinity of CBBR, the coomassie blue stain used for SDS
gel staining, bind to proteins via physisorption to arginine,
the aromatic amino acids, and histidine. Albumin, out of
its 650 amino acids is comparatively low in these amino
acids. Secondly, CBBR binds poorly to less soluble proteins in acidic medium.
Early research has shown association between HBV

and albumin, but not with albumin precursor as revealed
in this study. It is well established that human albumin is
initially synthesized as a proprotein and subsequently
transformed into serum albumin (Weigand and Alpert,
1981). The proalbumin, differs from circulating serum
albumin only in containing a basic hexapeptide, Arg-GlyVal-Phe-Arg-Arg, at its NH2 terminus (Peters, 1996).
Repeatedly conflicting views have been published
describing cooperation of so-called polymerized albumin
with HBV. It has been demonstrated that pHSA binds to
HBsAg particles (Pontisso et al., 1983) within the pre-S2
amino acid sequence (Machida et al., 1984). In 1989,
Pontisso and his colleagues, using the membranes of
surgically obtained human liver as a target, described the
role of HBV preS2 region as a specific site that binds the
poly-human albumin in vitro. They showed that pHSA is
necessary and sufficient for the attachment of pre-S2containing M-rHBsAg particles to human liver plasma
membranes. They also showed that pHSA enhances the
L-rHBsAg particle binding to these membranes. Other
investigators also reported similar findings with polyhuman albumin in vitro (Machida et al., 1983) and the
monomeric human albumin in vivo (Krone et al., 1990; Lu
et al., 1988), but it was neither investigated further nor
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confirmed. Other reports have demonstrated that native
and glutaraldehyde-polymerized albumins bind to hepatocytes (Lenkei et al., 1977; Trevisan et al., 1982; Wright et
al., 1987; Yu et al., 1987); however, presence of pHSA in
vivo has not been established. It is therefore, not clear
whether pHSA plays a role in HBV infection or not.
Preceding research did not report expression of
albumin precursor as binding protein of Hepatitis B Virus.
However, a number of proteins have been recognized as
HBV envelope binding proteins with a proposed role as
mediators in HBV attachment to the hepatocytes. These
proteins have been identified to interact with various HBV
domains. Thus, apolipoprotein H, (Mehdi et al., 1994) that
binds to S domain; human serum albumin and a human
soluble serum factor (Budkowska et al., 1993) and a 44
kDa protein (Falco et al., 2001) are to name a few in this
regard. Neurath and his colleagues in 1994 discovered
the binding site on pre-Sl domain from amino acid
sequence 21 to 47 which is involved in the recognition of
hepatocyte receptors. Recently, Blanchet and Sureau
(2007) by mapping the entire pre-S domain for infectivity
determinants demonstrated that the activity of the pre-S
domain at viral entry solely depends on the integrity of
only its first 75 amino acids. While De Falco et al. (2001)
identified a 44 kDa protein by using the pre-S1 peptide
originally shown to bind liver cells by Neurath et al.
(1994). None of the candidate proteins have demonstrated biological activity in HBV infectivity. Secondly, the L
protein is modified at the amino-terminal glycine of the
pre-S1 domain with a myristate (Persing, 1987), which is
required for infectivity (Bruss, 1996) and none of the
above described proteins to date have been identified
with a pre-S1 protein containing the amino-terminal myristate known to be essential for infectivity. These results
are conflicting, and no conclusive and convincing biological data has been obtained to fully demonstrate the
functional role of these proteins in HBV binding and internalization. Thus, the viral structures involved in attachment to the target cell were identified, but the binding
protein for HBV could not be positively deter-mined and
the biochemical events leading to infection remain unknown.
The binding of HBV with albumin precursor apparently
shows an evidence of a cargo role for albumin precursor
in the delivery of Hepatitis B virus to the hepatic cells.
The cargo chaperone function of albumin is to facilitate
the delivery across the vessel wall barrier. However, it is
not clear whether it only transports hydrophobic cargo
molecules to specific binding proteins on the endothelial
cell surface or it serves as an all purpose transporter
(Peters, 1995). As far as microorganisms are concerned
Albumin has been long realized as their ligand especially for
bacteria. Certain Gram-positive bacteria bind tightly to
albumins and IgG of various species has been recognized
since 1979. The albumin provides transport and possibly
nutrients to the invaders and increases their virulence
(Peters, 1995).
So far there is no documented evidence that could
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show the involvement of HBV with albumin precursor.
Binding of HBV may be achieved through myristate to
albumin precursor, which binds to receptor on the heaptocytes. Myristate has been found to have multiple (five)
binding site on Albumin molecule (Curry et al., 1998). The
very amino-terminal end of the pre-S1 domain, including
the myristate group attached to it, is a putative primary
receptor-binding domain (Blanchet and Sureau, 2006).
Basically, two sites on its small HbsAg protein have been
proposed by Cooper et al. (2003). One site is to attach to
the binding protein we propose albumin precursor and a
secondary attachment site that recognizes a distinct
receptor on the cell membrane, supporting the hypothesis
of a multivalent and cooperative mechanism of virus
attachment to the cell surface, as occurs for many other
viruses. Another factor that facilitates HBV binding to
proteins is the presence of QLDPAF sequence within pre
S 1 region, which has been found in all HBV samples we
studied.
Paran and his colleagues (2001) found that the
QLDPAF sequence within this preS1 region was crucial
for cell attachment. Further evidence to support this
hypothesis is that analysis of the database revealed that
this minimal epitope is shared by other viral, bacterial and
cellular proteins that participate in cell adhesion,
attachment and fusion. This suggests that the QLDPAF
sequence or part of it may play a role in cell adherence
and attachment.
Conclusion
Although many technical details remain to be explored,
yet on the basis of evidence presented in this study elucidates that HBV binds to albumin precursor and it would
not be unreasonable to propose that pre S region of HBV
might be the most likely domain involved. At this point it is
not clear yet how Human Albumin Precursor fulfills all of
these different functions, however, assuming that this protein acts as a chaperone, thereby stabilizing HBV structures, a function in these varied processes might be envisaged.
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